European investment firm LSP has launched a new dementia-focused fund to fill what it believes is a gap in support for development-stage companies evaluating treatments for neurodegenerative diseases. The firm has named Philip Scheltens, who...

As lightning-quick vaccine development comes close to catching up with a runaway pandemic, FDA must quickly decide how it will respond to the first clear signs that a vaccine candidate may be effective.  ...

An open letter from Pfizer’s Albert Bourla and a commentary from FDA’s heads of vaccine research and review respectively spell out how FDA’s guidance is shaping the timeline for what could be the first COVID-19...

Arrowhead gains on AAT deficiency dataArrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) gained nearly $1.4 billion in market cap Wednesday after sharing interim data from four alpha-antitrypsin (AAT) deficiency patients treated with ARO-AAT in the Phase II AROAAT2002...

With a fresh $55 million and a new publication detailing its nanoparticle-based technology, Seer thinks it can bring the scale and speed of next-generation sequencing to proteomics next year. On Wednesday, Seer announced a series...

Demand for COVID-19 therapies could far exceed supplies unless urgent steps are taken to prioritize and expand manufacturing capacity for the most promising therapeutic candidates, according to biopharma industry executives and public policy scholars. A...

Even if COVID-19 does disrupt operations or create a buyer’s market, Novartis will not veer from its business development strategy. The pharma was already expanding external innovation before the crisis, and has no intention of...

ReCode Therapeutics launched on Thursday with an OrbiMed- and Colt Ventures-led $80 million series A round to pair RNA therapeutics for rare respiratory diseases with an organ-specific lipid nanoparticle delivery technology. The company was formed...

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...